Share This Page
Suppliers and packagers for JUNEL FE 1.5/30
✉ Email this page to a colleague
JUNEL FE 1.5/30
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Barr | JUNEL FE 1.5/30 | ethinyl estradiol; norethindrone acetate | TABLET;ORAL-28 | 076064 | ANDA | Teva Pharmaceuticals USA, Inc. | 0555-9028-58 | 6 POUCH in 1 CARTON (0555-9028-58) / 1 BLISTER PACK in 1 POUCH / 1 KIT in 1 BLISTER PACK | 2003-09-18 |
| Barr | JUNEL FE 1.5/30 | ethinyl estradiol; norethindrone acetate | TABLET;ORAL-28 | 076064 | ANDA | A-S Medication Solutions | 50090-3122-0 | 6 POUCH in 1 CARTON (50090-3122-0) / 1 BLISTER PACK in 1 POUCH / 1 KIT in 1 BLISTER PACK | 2003-09-18 |
| Barr | JUNEL FE 1.5/30 | ethinyl estradiol; norethindrone acetate | TABLET;ORAL-28 | 076064 | ANDA | Teva Women's Health LLC | 51285-128-70 | 5 POUCH in 1 CARTON (51285-128-70) / 1 BLISTER PACK in 1 POUCH / 1 KIT in 1 BLISTER PACK | 2015-02-26 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: JUNEL FE 1.5/30
Introduction
JUNEL FE 1.5/30 is a combined oral contraceptive pill widely used for birth control and hormone regulation. Comprised of ethinyl estradiol (1.5 mg) and levonorgestrel (30 mcg), it belongs to a class of synthetic hormones designed to prevent ovulation and induce other contraceptive effects. As a regulated pharmaceutical, the supply chain for JUNEL FE 1.5/30 involves specialized pharmaceutical manufacturers, generic drug producers, and authorized distributors. This report delves into prominent suppliers involved in the manufacturing, sourcing, and distribution of this medication, providing an overview relevant to stakeholders across the healthcare supply chain.
Key Manufacturers and Brand Leaders
While JUNEL FE 1.5/30 is a branded product primarily associated with Teva Pharmaceuticals, a global leader in generics and branded pharmaceuticals, numerous manufacturers produce similar formulations under different brand names or as generics. The landscape among suppliers includes both original developers and generic producers operating under strict regulatory oversight.
1. Teva Pharmaceuticals
Teva is the principal originator and distributor of JUNEL FE 1.5/30, with manufacturing facilities strategically located in North America, Europe, and Asia. As a leading global generic drug manufacturer, Teva holds multiple FDA approvals for the production of oral contraceptives, ensuring compliance with United States Pharmacopeia (USP) standards and Good Manufacturing Practices (GMP).
Supply Role:
Teva acts as both the patent-holder for the original formulation and a primary supplier to healthcare providers and pharmacies. Its extensive distribution network guarantees Europe, North America, and other regions access to authentic JUNEL FE 1.5/30.
2. Mylan (now part of Viatris)
Viatris, formed from the merger of Mylan and Pfizer’s Upjohn unit, produces a wide array of contraceptive formulations, including generic equivalents to JUNEL FE 1.5/30.
Supply Role:
Viatris supplies generic versions under their own labels, meeting regulatory approvals across multiple jurisdictions. Their manufacturing facilities in the US, India, and Europe meet GMP standards, positioning them as a significant alternative supplier.
3. Sandoz (Novartis)
Sandoz, Novartis’ generics division, offers contraceptive medications similar in formulation to JUNEL FE 1.5/30. They serve markets in Europe, North America, and emerging economies.
Supply Role:
Manufacturing plants adhere to GMP standards, with prequalified supply chains ensuring consistent quality. Sandoz’s inclusion in global tenders and government supply contracts enhances their role in supplying affordable contraceptive options.
4. Hikma Pharmaceuticals
Hikma is a key player in the Middle Eastern, North African, and European markets, producing oral contraceptive formulations compatible with JUNEL FE 1.5/30.
Supply Role:
Hikma’s manufacturing facilities in Jordan and the UK produce reproductive health medications meeting international quality standards, broadening supply options in various territories.
5. Local and Regional Generic Suppliers
Numerous regional pharmaceutical companies manufacture and distribute generic versions of oral contraceptives, including variants with the same active ingredients. Notably, Indian companies such as Lupin, Cipla, and Aurobindo Pharma are significant contributors to the global supply chain, especially for low- and middle-income countries.
Supply Role:
These companies often supply through local distributors, governmental procurement programs, or international aid agencies, thus amplifying access to contraceptives universally.
Regulatory Considerations and Authorized Distributors
Manufacturers and suppliers must navigate complex regulatory environments governed by agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other national bodies. Several suppliers maintain active regulatory approvals, ensuring their products' legal distribution across regions.
Authorized distributors often include major pharmaceutical wholesalers like McKesson, Cardinal Health, and Henry Schein in North America, and Alliance Healthcare or Phoenix Group in Europe. These entities facilitate logistics, storage, and distribution to pharmacies and healthcare providers, ensuring consistent drug availability.
Supply Chain Dynamics and Market Trends
The supply of JUNEL FE 1.5/30 is influenced by factors such as regulatory approvals, manufacturing capacity, patent status, and global demand for oral contraceptives. With the increasing emphasis on generic and biosimilar markets, numerous manufacturers are expanding their portfolios, which could impact supply stability and pricing.
Post-patent expiry and generics proliferation have resulted in increased competition, often leading to improved affordability and broader access, especially in low-income regions. However, manufacturing disruptions, regulatory hurdles, and supply chain bottlenecks can challenge consistent availability.
Emerging Suppliers and Future Outlook
Advancements in manufacturing technologies, such as continuous manufacturing and quality-by-design (QbD), are enabling new entrants to participate in the supply of hormone-based contraceptives like JUNEL FE 1.5/30. Countries with burgeoning pharmaceutical sectors, including China, India, and Brazil, are gaining prominence as exporters of generic contraceptives.
Future supply chain considerations include:
- Expanding manufacturing capacity to meet increasing global demand, especially in developing markets.
- Ensuring regulatory harmonization to facilitate cross-border supply.
- Strengthening supply chain resilience against geopolitical tensions and logistical disruptions.
- Emphasizing quality assurance amidst proliferation of generic alternatives.
Key Takeaways
- Main Suppliers: Teva Pharmaceuticals remains the primary provider of JUNEL FE 1.5/30, complemented by generic producers like Viatris, Sandoz, and Hikma.
- Global Distribution: A diverse network of regional generic manufacturers, especially from India and Europe, contribute substantially to worldwide availability.
- Regulatory Compliance: Only products with proper approvals from authorities such as FDA and EMA are eligible for legal distribution, emphasizing the importance of quality standards.
- Market Dynamics: Increased competition from generics has improved access and affordability but requires ongoing vigilance in manufacturing quality and supply chain resilience.
- Future Trends: Emerging markets and technological advancements promise new suppliers and expanded production capacity, promising stable availability of this contraceptive.
FAQs
1. Are there any licensed alternative manufacturers for JUNEL FE 1.5/30?
Yes. While Teva is the original manufacturer, multiple licensed generic manufacturers such as Viatris, Sandoz, and Hikma produce comparable formulations with regulatory approvals, ensuring legal and quality standards.
2. How does patent status impact the supply of JUNEL FE 1.5/30?
The original patent protections influence market exclusivity. Once patents expire, generic companies enter the market, increasing supply options. Post-patent expiry, multiple suppliers typically emerge, broadening access.
3. Can regional generic producers supply JUNEL FE 1.5/30 globally?
Yes. Many regional producers, especially from India and Europe, hold licensing agreements and meet international GMP standards, permitting them to supply in various global markets.
4. What are the risks to the supply chain of JUNEL FE 1.5/30?
Supply disruptions can result from manufacturing issues, regulatory delays, geopolitical tensions, or logistical failures. Suppliers’ adherence to strict quality standards minimizes risks but cannot eliminate them entirely.
5. How does the global demand for contraceptives influence the supply of JUNEL FE 1.5/30?
Rising demand, especially in developing regions, prompts manufacturers to expand capacity and enter new markets. This demand-driven growth encourages competition, innovation, and supply chain resilience.
References:
[1] U.S. Food and Drug Administration (FDA). Approved Drug Products Database.
[2] European Medicines Agency (EMA). Human Medicines Evaluation Reports.
[3] Teva Pharmaceuticals Official Website. Product Portfolio.
[4] Viatris Corporate Website. Contraceptive Products.
[5] Sandoz Global Portfolio.
[6] Hikma Pharmaceuticals Public Website. Product Manufacturing.
More… ↓
